After 18 years in development, AstraZeneca's CTLA-4 antibody gets the red carpet treatment at the FDA - Endpoints News

4/25/2022 12:00:00 AM3 yearsago
by Jason Mast

After a decade, a second CTLA-4 antibody may finally be on its way to approval. AstraZeneca announced Monday that the FDA had given priority review to tremelimumab, its long-gestating CTLA-4 antibody, in combination with the PD-L1 inhibitor Imfinzi for patien…

Af­ter a decade, a sec­ond CT­LA-4 an­ti­body may fi­nal­ly be on its way to ap­proval. As­traZeneca an­nounced Mon­day that the FDA had giv­en pri­or­i­ty re­view to treme­li­mum­ab, its long-ges­t… [+2315 chars]

full article...